Oncology and Hematology - Global Oncology Academy

193-208 of 663

Next-Generation Horizons in PNH Therapies
Next-Generation Horizons in PNH Therapies
Project Oncology®
Next-Generation Horizons in PNH Therapies
Vinod Pullarkat, MD
- Vinod Pullarkat, MD
Advances in Colorectal Cancer Detection: Exploring the Role of Blood-Based Tests
Advances in Colorectal Cancer Detection: Exploring the Role of Blood-Based Tests
GI Insights
Advances in Colorectal Cancer Detection: Exploring the Role of Blood-Based Tests
Peter Buch, MD, FACG, AGAF, FACP; Aasma Shaukat, MD, MPH
- Peter Buch, MD, FACG, AGAF, FACP
- Aasma Shaukat, MD, MPH
Managing PNH: Clinical Considerations
Managing PNH: Clinical Considerations
Project Oncology®
Managing PNH: Clinical Considerations
Charles Turck, PharmD, BCPS, BCCCP; Jamie Koprivnikar, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Jamie Koprivnikar, MD
- Abdulraheem Yacoub, MD
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Heart Matters
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Jun-ichi Abe
- Jun-ichi Abe
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Project Oncology®
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Ryan Quigley
- Ryan Quigley
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
Project Oncology®
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Project Oncology®
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Project Oncology®
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Project Oncology®
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
MinuteCE®
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
Joyce F. Liu, MD, MPH
0.50 program credits
- Joyce F. Liu, MD, MPH
0.50 program credits
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
MinuteCE®
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Joyce F. Liu, MD, MPH; Kathleen Moore, MD, MS
0.50 program credits
- Joyce F. Liu, MD, MPH
- Kathleen Moore, MD, MS
0.50 program credits
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
MinuteCE®
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
Joyce F. Liu, MD, MPH
0.50 program credits
- Joyce F. Liu, MD, MPH
0.50 program credits
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
MinuteCE®
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
Kathleen Moore, MD, MS
0.50 program credits
- Kathleen Moore, MD, MS
0.50 program credits
MinuteCE®
CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian Cancer
Kathleen Moore, MD, MS; Joyce F. Liu, MD, MPH
0.50 credits 5 episodes
- Kathleen Moore, MD, MS
- Joyce F. Liu, MD, MPH
0.50 credits 5 episodes
MOA: CDH6-Targeted Antibody-Drug Conjugates
MOA: CDH6-Targeted Antibody-Drug Conjugates
MinuteCE®
MOA: CDH6-Targeted Antibody-Drug Conjugates
Kathleen Moore, MD, MS
0.50 program credits
- Kathleen Moore, MD, MS
0.50 program credits
Obesity and Cancer Screening: National Trends and Disparities Revealed
Obesity and Cancer Screening: National Trends and Disparities Revealed
Clinician's Roundtable
Obesity and Cancer Screening: National Trends and Disparities Revealed
Vance Albaugh, MD, PhD
- Vance Albaugh, MD, PhD

13/11